Probiotyki a infekcja Helicobacter pylori

• Autorzy: Grodowska A , Jarosz M.

Warianty tytułu

EN

Probiotics and Helicobacter pylori infection

• Języki publikacji: PL

Słowa kluczowe

PL

zastosowanie; badania kliniczne; probiotyki; infekcja bakteryjna; Helicobacter pylori; kultury bakteryjne; bakterie kwasu mlekowego

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2006
• Tom: 33
• Numer: 4
• Opis fizyczny: s.326-335,tab.,bibliogr.

Twórcy

autor

Grodowska A

• Instytut Zywnosci i Zywienia, Warszawa

autor

Jarosz M.

Bibliografia

• 1. www.who.int/foodsafety/publications/fs_management/probiotics/en/-19k.
• 2. Füller R.: Probiotics in man and animals. J. Appl. Bacteriol., 1989, 66, 365-378.
• 3. Woźniak-Kosek A., Jarosz M.: Probiotyki a żywienie człowieka. Żyw. Człow. Metab., 2005, 1, 72-83.
• 4. Łękowska-Kochaniak A.: Enterokoki (paciorkowce kałowe) - probiotyki czy patogeny? Post. Mikrobiol., 2000, 39, 4, 341-361.
• 5. Gill H., Guarner F.: Probiotics and human health: a clinical perspective. Postgrad. Med. J., 2004, 80, 516-526.
• 6. Włodarek D.: Probiotyki i prebiotyki. Med. Po Dypl. 2004, 13, (11), 119-124.
• 7. Mercenier A., Pavan S., Pot B.: Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr. Pharm. Design, 2003, 9, 175-191.
• 8. Salminen S., Gueimonde M., Isolauri E.: Probiotics That Modify Disease Risk. J. Nutr., 2005, 135, 1294-1298.
• 9. www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.
• 10. Bielański W., Ziemniak M., Płonka M., i wsp.: Enhancement of Helicobacter pylori eradication rate in polish patients by use of commercially available probiotics. Proceedings of Annual Scientific Exchange 2003, September 12-14 2003, Quebec City, Canada.
• 11. Bartnik W., Przytulski K., Tomecki R., Zych W.: Nowotwory złośliwe żołądka. Interna pod red: W.J. Januszewicza, F. Kokota, PZWL, Warszawa, 2001, t. 1.
• 12. Matysiak-Budnik T., Mégraud F.: Helicobacter pylori infection and gastric cancer. Eur. J. Cancer., 2006, 42, 708-716.
• 13. Malferheiner P., Megraud F, O” Morain C.: Guidelines for the management of Helicobacter pylori infection. Business Briefing: European Gastroenterology Review 2005.
• 14. Oderda G., Marinello D., Lerro P., i wsp.: Dual vs. triple theraphy for childchood Helicobacter pylori gastritis (a doubleblind randomized multicentre trial). Helicobacter 2004, 9, 293-301.
• 15. Gottrand F., Kalach N., Spyckerelle C., i wsp.: Omeprazole combined with amoxycillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis (a prospective randomized double-blind trial). J. Pediatr., 2001, 139, 664-668.
• 16. Canducci F., Cremonini F., Armuzzi A., i wsp.: Probiotics and Helicobacter pylori eradication. Digest. Liver Dis., 2002, 34 (suppl. 2), 81-3.
• 17. Dzieniszewski J., Jarosz M.: Guidelines: in the medical treatment of Helicobacter pylori infection. J. Physiol. Pharm., 2006, 57, 3, 155-161.
• 18. Paradowski L., Błachut K., Annabhani A.: Konsensus Maastricht III. Co nowego? Gastroenterol. Pol., 2006, 13, 335-336.
• 19. Go M.: Diagnosis and treatment of Helicobacter pylori. Curr. Treatm. Options Gastroenterol., 2005, 8, 163-174.
• 20. Francavilla R., Lionetti E., Castellaneta S.: Improved efficacy of 10-day treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005, 129, 1414-1419.
• 21. Zullo A., Vaira D., Vakil N.: High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment. Pharmacol. Ther., 2003, 17, 719-726.
• 22. Aebischer T., Schmitt A.,WalduckA.: Helicobacter pylori vaccine development: facing the challenge. Int. J. Med. Microbiol., 2005, 295, (5), 343-53.
• 23. Di Mario F., Aragona G., Dal Bo N.: Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment. Pharmacol. Ther., 2006, 23, (8), 1235-40.
• 24. Legrand D., Elass E., Carpentier M.: Lactoferrin: a modulator of immune responses. Cell. Mol. Life Sci., 2005, 62, (22), 2549-59.
• 25. Legrand D., Elass E., Pierce A.: Lactoferrin and host defence: an overview of its: immuno-modulatory properties. Biometals 2004, 17, (3), 225-9.
• 26. Ward P., Uribe-Luna S., Conneely O.: Lactoferrin and host defence. Biochem. Cell. Biol., 2002, 80, (1), 95-102.
• 27. Martin K., Ernst E.: Herbal medicines for treatment of bacterial infections; a review of controlled trials. J. Antimicrob. Chemother., 2003, 51, (2), 241-6.
• 28. O’Mahony R., Al-Khtheeri H., Weerasekera D.: Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World Gastroenterol., 2005, 11, (47), 7499-507.
• 29. Jenab M., Riboli E., Ferrari P.: Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Carcinogenesis 2006, 27, (11), 2250-2259.
• 30. Simon J., Hudez E., Perez-Perez G.: Relation of serum ascorbic acid to Helicobacter pylori serology: in US adults: the Third National Heath and Nutriton Examination Survey. J. Am. Coll. Nutr., 2003, 22, (4), 283-0.
• 31. Woźniak-Kosek A., Jarosz.M.: Probiotyki a prewencja i leczenie chorób przewodu pokarmowego człowieka. Żyw. Człow. Metab., 2005, 4, 366-375.
• 32. Isolauri E., Sutas Y., Kankaanpaa P: Probiotics: effect on immunity. Am. J. Clin. Nutr., 2001, 73, (2 suppl), 444S-450S.
• 33. Michetti P., Dorta D., Wiesel H., i wsp.: Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsoni) La1on Helicobacter pylori infection in humans. Digestion 1999, 60, 203-209.
• 34. Aiba Y., Suzuki N., Kabir A., i wsp.: Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in gnotobiotic murine model. Am. J. Gastroenterol., 1998, 93, 2097-2101.
• 35. Coconnier M., Lievin V., Hemery E.: Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl. Environ. Microbiol., 1998, 64, (11), 4573-80.
• 36. Sqouras D., Maraqkoudakis S., Petraki K.: In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ. Microbiol., 2004, 70, (1), 518-26.
• 37. Johnson-Henry K., Mithell D., Avitzur Y., i wsp.: Probiotics reduce bacterial colonization and gastric inflamation in H. pylori-infected mice. Dig. Dis. Sci., 2004, 49(7-8), 1095-1102.
• 38. Ushiyama A., Tanaka K., Aiba Y, i wsp.: Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin- resistant Helicobacter pylori infection. J. Gastroenterol. Hepatol., 2003, 18, (8), 986-991.
• 39. Kabir A., Aiba Y., Takagi S., i wsp.: Prevention of Helicobacter infection by lactobacilli in a gnobiotic murine model. GUT 1997, 41, 49-55.
• 40. Wendakoon C., Thomson A., Ozimek L.: Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori infection. Digestion 2002, 65, 16-20.
• 41. Canducci F., Armuzzi A., Cremonini F., i wsp.: A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment. Pharmacol. Ther., 2000, 14, (12), 1625-9.
• 42. Sýkora J., Valeèková M., Amlerová J., i wsp.: Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children. J. Clin. Gastroenterol., 2005, 39, 692-698.
• 43. Glupczynski Y., Mégraud F., Lopez-Brea M., i wsp.: European multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis., 2000, 11, 820- 23.
• 44. Dzierżanowska-Fangrat K., Rozynek E., i wsp.: Antimicrobial resistance of Helicobacter pylori: in Poland: a multicentre study. Int. J. Antimicrob. Ag., 2005, 26, (3), 230-234.
• 45. Plewińska E., Płaneta-Małecka I., Bąk-Romaniszyn L.: Probiotics in the treatment of Helicobacter pylori infection in children. Gastroenterol. Pol., 2006, 13, (4), 315-319.
• 46. Armuzzi A., Cremonini F., Bartolozzi F., i wsp.: The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication theraphy. Aliment. Pharmacol. Ther., 2001, 15, 163-169.
• 47. Armuzzi A., Cremonini F., Ojetti V., i wsp.: Effect of Lactobacillus GG supplementation on antibiotic - associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001, 63: 1-7.
• 48. Cremonini F., Di Caro S., Covino M., i wsp.: Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo controlled study. Am. J. Gastroenterol., 2002, 97, 2744-2749.
• 49. Nista E., Candelli M., Cremonini F., i wsp.: Bacillus clausi therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment. Pharmacol. Ther., 2004, 20, 1181-1188.
• 50. Myllyluoma E., Veijola L., Ahlroos T., i wsp.: Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy- a placebo- controlled, double-blind randomized pilot study. Aliment. Pharmacol. Ther., 2005, 21, 1263-1272.
• 51. Tursi A., Brandimarte G., Giorgetti G., i wsp.: Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med. Sci. Monit., 2004, 10, CR662-666.
• 52. Cremonini F., Di Caro S., Covino M.: Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo controlled study. Am. J. Gastroenterol., 2002, 97, (11), 2744-2749.
• 53. Felley C., Corthesy-Theulaz I., i wsp.: Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur. J. Gastroenterol. Hepatol., 2001, 13, (1), 25-9.